Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 312
Selected: 0
NCT IDTitle
NCT03369236A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
NCT04925804Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)
NCT05288660A Study of a Single Dose of ALXN1210 in Healthy Participants
NCT05683678US Selumetinib Registry
NCT06398158Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
NCT00952484Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
NCT05368038ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
NCT03310021A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
NCT05501717Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
NCT02345421A Study to Identify and Characterize LAL-D Patients in High-risk Populations
NCT01203826Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)
NCT03218241Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
NCT03578146Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)
NCT05288816A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
NCT03083704A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
NCT05097989Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT05303324Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
NCT02112994Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
NCT03403205Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
NCT01892345A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
NCT05389449A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT03920293Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
NCT02193867Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
NCT05234567A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT04623710Study of ALXN2050 in Participants With Renal Impairment
NCT07024563Study of Ravulizumab in Pediatric Participants With Primary IgAN
NCT02949128Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT06183931Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT03384186A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
NCT05506254Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy
NCT05778071Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05686564Early Access Program for ALXN1840 in Patients With Wilson Disease
NCT04021082CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
NCT01163149Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
NCT04970004Study in Adult and Pediatric Patients With HSCT-TMA
NCT05319912A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT00675844An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
NCT04189315Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease
NCT02220725A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
NCT05314231Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
NCT02003144An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
NCT01716728Identification of Undiagnosed Lysosomal Acid Lipase Deficiency
NCT02618512A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
NCT04202341Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04248465An Efficacy and Safety Study of Ravulizumab in ALS Participants
NCT01419028A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
NCT01757184Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency
NCT03574506Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series
NCT04958135Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants